Calderasib clinical trials
Calderasib is named as an intervention in 10 current clinical trials in our Spain, USA, China, Italy, South Korea, Poland, Turkey, Canada, Japan, Australia, UK, France, Brazil, Israel, Netherlands, Taiwan, Germany, Switzerland, Mexico, Austria, Denmark, Belgium, Singapore, India, Sweden and Norway registers. 9 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is Merck Sharp & Dohme LLC. The most-studied condition is Non-small Cell Lung Cancer. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
Patient leaflets for Calderasib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Calderasib
10 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Calderasib in the EU trials register (CTIS)
2 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Calderasib. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)
2025-522038-29-00 · Neoplasms
|
Phase 3 | Ongoing | Merck Sharp & Dohme LLC | Italy, Netherlands, France + 4 more |
|
Protocol Title: KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations
2024-512248-47-00 · CTIS ↗ · Neoplasms
|
Phase 1 | Ongoing | Merck Sharp & Dohme LLC | Italy, Germany, Greece + 3 more |
Conditions studied with Calderasib
8 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 10 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Calderasib trials
How many clinical trials are testing Calderasib?
10 current trials in our Spain, USA, China, Italy, South Korea, Poland, Turkey, Canada, Japan, Australia, UK, France, Brazil, Israel, Netherlands, Taiwan, Germany, Switzerland, Mexico, Austria, Denmark, Belgium, Singapore, India, Sweden and Norway registers name Calderasib (also registered as MK-1084) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Calderasib trials recruiting patients?
Yes. 9 of the 10 trials are recruiting: 9 with sites in Spain, 8 with sites in USA, 9 with sites in China, 9 with sites in Italy, 9 with sites in South Korea, 7 with sites in Poland, 8 with sites in Turkey, 6 with sites in Canada, 7 with sites in Japan, 7 with sites in Australia, 6 with sites in UK, 6 with sites in France, 6 with sites in Brazil, 5 with sites in Israel, 5 with sites in Netherlands, 5 with sites in Taiwan, 5 with sites in Germany, 2 with sites in Switzerland, 3 with sites in Mexico, 2 with sites in Austria, 2 with sites in Denmark, 1 with sites in Belgium, 1 with sites in Singapore, 1 with sites in India, 1 with sites in Sweden and 1 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Calderasib clinical trials?
The lead sponsor is Merck Sharp & Dohme LLC. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Calderasib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Calderasib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Calderasib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.